Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
37.05
-0.79 (-2.09%)
At close: Sep 18, 2026, 4:00 PM EDT
37.63
+0.58 (1.57%)
After-hours: Sep 18, 2026, 7:37 PM EDT
Cue Biopharma Revenue
Cue Biopharma had revenue of $7.88M in the quarter ending June 30, 2026, with 166.66% growth. This brings the company's revenue in the last twelve months to $37.65M, up 354.37% year-over-year. In the year 2025, Cue Biopharma had annual revenue of $27.47M with 195.75% growth.
Revenue (ttm)
$37.65M
Revenue Growth
+354.37%
P/S Ratio
7.15
Revenue / Employee
$1,298,448
Employees
29
Market Cap
269.15M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 27.47M | 18.18M | 195.75% |
| Dec 31, 2024 | 9.29M | 3.80M | 69.16% |
| Dec 31, 2023 | 5.49M | 4.25M | 340.96% |
| Dec 31, 2022 | 1.25M | -13.70M | -91.67% |
| Dec 31, 2021 | 14.94M | 11.79M | 373.68% |
| Dec 31, 2020 | 3.15M | -304.01K | -8.79% |
| Dec 31, 2019 | 3.46M | 2.32M | 202.67% |
| Dec 31, 2018 | 1.14M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 175.14M |
| Fulcrum Therapeutics | 80.00M |
| AC Immune | 21.67M |
| ProQR Therapeutics | 21.05M |
| Lineage Cell Therapeutics | 13.08M |
| Pyxis Oncology | 11.04M |
| Upstream Bio | 3.16M |
| Lyell Immunopharma | 27.00K |
CUE News
- 1 day ago - Cue Biopharma initiated with a Buy at B. Riley - TheFly
- 4 weeks ago - Cue Biopharma registers to sell 1.5M shares of common stock for holders - TheFly
- 5 weeks ago - Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 5 weeks ago - Cue Biopharma Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Cue Biopharma Earnings release: Q2 2026 - Filings
- 5 weeks ago - Cue Biopharma Registration statement: Registration filing - Filings
- 6 weeks ago - Cue Biopharma appoints James Ahlers as CFO - TheFly
- 6 weeks ago - Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission - GlobeNewsWire